Osteoporosis is a chronic, systemic, and often asymptomatic disease. Although physician-specialists are involved in the treatment, it would be a big mistake to omit pharmacists.
The pharmacist can contribute to the identification of patients at risk of fractures by revealing risk factors or drug-related problems, as well as provide advice on prevention and assist in patient education focused on adhering to the treatment plan. This may importantly influence the treatment outcomes and minimize potential risks of therapy, including the support of compliance.
The aim of the paper is to outline possibilities of pharmaceutical care of patients with osteoporosis.